Phase II Study of Concurrent Administration of Doxorubicin and Docetaxel as First-Line Chemotherapy for Metastatic Breast Cancer

Publisher： Karger

E-ISSN： 1423-0232|64|2|124-130

ISSN： 0030-2414

Source： Oncology, Vol.64, Iss.2, 2003-02, pp. : 124-130

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Phase II Trial of Docetaxel and Carboplatin as First-Line Chemotherapy for Metastatic Breast Cancer: NCCTG Study N9932

By  

Oncology, Vol. 69, Iss. 2, 2005-09 ,pp. : 117-121

Karger

Access to resources Recommend Favorite

Phase II Trial of Pegylated Liposomal Doxorubicin-Cyclophosphamide Combination as First-Line Chemotherapy in Older Metastatic Breast Cancer Patients

By  

Oncology, Vol. 73, Iss. 3-4, 2008-04 ,pp. : 210-214

Karger

Access to resources Recommend Favorite

A Phase I Dose-Escalating and Pharmacokinetic Study of Docetaxel and Vinorelbine as First-Line Chemotherapy for Metastatic Breast Cancer

By  

Oncology, Vol. 72, Iss. 5-6, 2008-01 ,pp. : 322-325

Karger

Access to resources Recommend Favorite

Weekly Docetaxel and Gemcitabine as First-Line Treatment for Metastatic Breast Cancer: Results of a Multicenter Phase II Study

By  

Oncology, Vol. 68, Iss. 4-6, 2005-08 ,pp. : 438-445

Karger

Access to resources Recommend Favorite

Prospective Multicenter Randomized Phase III Study of Weekly versus Standard Docetaxel plus Doxorubicin (D4) for First-Line Treatment of Metastatic Breast Cancer

By  

Oncology, Vol. 79, Iss. 3-4, 2011-03 ,pp. : 204-210

Karger

Access to resources Recommend Favorite